Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +27.71% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$4M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -41%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $2M covers the $769889 due within a year 2.3× over. Scheduled principal only (excludes interest & revolver draws). As of 2023-12-31 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~12.2% on $2M of debt.
Cash of $2M fully covers short-term debt of $577898.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.1M 100.0% | $19.1M 100.0% | $21.0M 100.0% | $15.7M 100.0% | $10.7M 100.0% | $9.9M 100.0% | $6.8M 100.0% | $4.0M 100.0% | $3.2M 100.0% | $3.9M 100.0% |
| Cost of Revenue | $15.7M 82.2% | $13.3M 69.7% | $13.3M 63.2% | $10.8M 68.6% | $7.2M 67.8% | $6.6M 66.1% | $4.7M 68.8% | $2.6M 63.3% | $2.4M 75.5% | $3.0M 75.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $2.4M 75.5% | $3.0M 75.9% |
| Gross Profit | $3.4M 17.8% | $5.8M 30.3% | $7.7M 36.8% | $4.9M 31.4% | $3.4M 32.2% | $3.4M 33.9% | $2.1M 31.2% | $1.5M 36.7% | $774K 24.5% | $942K 24.1% |
| Research & Development | $1.2M 6.1% | $982K 5.1% | $992K 4.7% | $666K 4.3% | $624K 5.8% | $886K 8.9% | $505K 7.4% | $456K 11.3% | $464K 14.7% | $478K 12.2% |
| Selling, General & Admin | $7.8M 40.8% | $7.5M 39.5% | $7.4M 35.1% | $5.6M 35.8% | $3.7M 34.8% | $3.9M 39.3% | $2.1M 30.9% | $1.4M 34.0% | $1.3M 41.6% | $1.6M 39.6% |
| Total Operating Expenses | $9.0M 46.9% | $8.5M 44.6% | $8.4M 39.8% | $6.4M 41.1% | $4.3M 40.6% | $4.8M 48.2% | $2.7M 40.2% | $1.8M 45.3% | $1.8M 56.3% | $2.0M 51.0% |
| Operating Income | -$5.6M -29.1% | -$2.7M -14.3% | -$639K -3.0% | -$1.5M -9.7% | -$906K -8.5% | -$1.4M -14.3% | -$613K -9.0% | -$349K -8.6% | -$1.0M -31.8% | -$1.1M -26.9% |
| Interest Expense | $227K 1.2% | $225K 1.2% | $219K 1.0% | $156K 1.0% | $5K 0.0% | $1K 0.0% | $1K 0.0% | $2K 0.0% | $3K 0.1% | $469 0.0% |
| Pretax Income | -$5.8M -30.3% | -$2.9M -15.4% | -$143K -0.7% | -$927K -5.9% | -$102K -1.0% | -$1.4M -14.3% | -$614K -9.0% | -$350K -8.7% | -$1.0M -31.9% | -$1.0M -26.4% |
| Income Tax Expense | $2K 0.0% | $2K 0.0% | $2K 0.0% | $952 0.0% | $912 0.0% | $2K 0.0% | $912 0.0% | $912 0.0% | $912 0.0% | $912 0.0% |
| Net Income | -$5.8M -30.3% | -$3.0M -15.4% | -$145K -0.7% | -$928K -5.9% | -$103K -1.0% | -$1.4M -14.4% | -$615K -9.0% | -$351K -8.7% | -$1.0M -31.9% | -$1.0M -26.4% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.85 | $-0.49 | $-0.03 | $-0.18 | $-0.01 | — | $-0.05 | $-0.04 | $-0.12 | $-0.15 |
| EPS (Diluted) | $-0.85 | $-0.49 | $-0.03 | $-0.18 | $-0.01 | — | $-0.05 | $-0.04 | $-0.12 | $-0.15 |
| Weighted Avg Shares (Basic) | 6.8M | 6.1M | 5.7M | 5.3M | 13.3M | 13.0M | 11.5M | 9.8M | 8.3M | 7.2M |
| Weighted Avg Shares (Diluted) | 6.8M | 6.1M | 5.7M | 5.3M | 13.3M | — | — | — | 8.3M | 7.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 26 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 63.3 | 68.8 | 66.1 | 67.8 | 68.6 | 63.2 | 69.7 | 82.2 |
| Gross Profit | 36.7 | 31.2 | 33.9 | 32.2 | 31.4 | 36.8 | 30.3 | 17.8 |
| R&D | 11.3 | 7.4 | 8.9 | 5.8 | 4.3 | 4.7 | 5.1 | 6.1 |
| SG&A | 34.0 | 30.9 | 39.3 | 34.8 | 35.8 | 35.1 | 39.5 | 40.8 |
| Operating Income | -8.6 | -9.0 | -14.3 | -8.5 | -9.7 | -3.0 | -14.3 | -29.1 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -8.7 | -9.0 | -14.4 | -1.0 | -5.9 | -0.7 | -15.4 | -30.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on POCI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| POCI | $34M | — | — | 1.8× | -0.1% | 17.8% | -30.3% | -47.2% | -40.9% | -0.3× | 26 |
Peers = companies sharing POCI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.